BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solga SF, Buckley G, Clark JM, Horska A, Diehl AM. The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 2008;42:1117-9. [PMID: 18936646 DOI: 10.1097/MCG.0b013e31816d920c] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gart E, Souto Lima E, Schuren F, de Ruiter CGF, Attema J, Verschuren L, Keijer J, Salic K, Morrison MC, Kleemann R. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD. Int J Mol Sci 2018;20:E1. [PMID: 30577415 DOI: 10.3390/ijms20010001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
2 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
3 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
4 Fallucca F, Fontana L, Fallucca S, Pianesi M. Gut microbiota and Ma-Pi 2 macrobiotic diet in the treatment of type 2 diabetes. World J Diabetes 2015;6:403-11. [PMID: 25897351 DOI: 10.4239/wjd.v6.i3.403] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
6 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
7 Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon. 2013;13:e7521. [PMID: 23610585 DOI: 10.5812/hepatmon.7521] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
8 Horvath A, Leber B, Feldbacher N, Tripolt N, Rainer F, Blesl A, Trieb M, Marsche G, Sourij H, Stadlbauer V. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur J Nutr 2020;59:2969-83. [PMID: 31729622 DOI: 10.1007/s00394-019-02135-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
9 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
10 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
11 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 314] [Article Influence: 40.7] [Reference Citation Analysis]
12 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 67] [Article Influence: 12.7] [Reference Citation Analysis]
13 Sato Y. Encounter with childbirth in a sitting position. Josanpu Zasshi. 1985;39:802-803. [PMID: 3854811 DOI: 10.7812/tpp/12-144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
14 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777-3785. [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 57] [Article Influence: 13.2] [Reference Citation Analysis]
15 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
16 Hernandez GV, Smith VA, Melnyk M, Burd MA, Sprayberry KA, Edwards MS, Peterson DG, Bennet DC, Fanter RK, Columbus DA, Steibel JP, Glanz H, Immoos C, Rice MS, Santiago-Rodriguez TM, Blank J, VanderKelen JJ, Kitts CL, Piccolo BD, La Frano MR, Burrin DG, Maj M, Manjarin R. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastrointest Liver Physiol 2020;318:G582-609. [PMID: 32003601 DOI: 10.1152/ajpgi.00344.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
17 Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care. 2010;33:2277-2284. [PMID: 20876708 DOI: 10.2337/dc10-0556] [Cited by in Crossref: 360] [Cited by in F6Publishing: 301] [Article Influence: 36.0] [Reference Citation Analysis]
18 Yin YN, Yu QF, Fu N, Liu XW, Lu FG. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol. 2010;16:3394-3401. [PMID: 20632441 DOI: 10.3748/wjg.v16.i27.3394] [Cited by in CrossRef: 134] [Cited by in F6Publishing: 116] [Article Influence: 12.2] [Reference Citation Analysis]
19 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
20 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518-15531. [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 75] [Article Influence: 14.3] [Reference Citation Analysis]
21 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
22 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Reference Citation Analysis]